secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2025-05-16T23:59:59+00:00
Accession:  0001193125-25-121714
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora receives Nasdaq minimum bid price deficiency notice; has until Nov 10, 2025 to cure
--------------------------------------------------------------------------------

- Nasdaq notified Neumora on May 14, 2025 that its stock failed to meet the $1.00 minimum bid price requirement.
- Company has 180 calendar days, until November 10, 2025, to regain compliance by closing at $1.00+ for 10 consecutive business days.
- If not compliant by Nov 10, 2025, Neumora may seek transfer to Nasdaq Capital Market and additional cure period.
- Board approved a reverse stock split (1-for-5 to 1-for-30) subject to stockholder vote at Annual Meeting on May 28, 2025.
- Neumora intends to monitor bid price and consider options including the reverse split to maintain listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525121714/0001193125-25-121714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525121714/d933150d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-121714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer